Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€50.47

€50.47

-0.430%
-0.22
-0.430%
€84.13
 
10:42 / Tradegate WKN: A0D9T1 / Symbol: DXCM / Name: DexCom / Stock / Healthcare Equipment & Supplies / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Financial data and news for DexCom

sharewise wants to provide you with the best news and tools for DexCom, so we directly link to the best financial data sources.

News

From Dividends to Growth: Why These 3 Stocks Stand Out in 2025: https://www.marketbeat.com/logos/articles/med_20251105093343_dont-ignore-3-firms-with-rising-dividends-and-buy.jpg
From Dividends to Growth: Why These 3 Stocks Stand Out in 2025

It's rare for an attractive dividend stock also to have growth potential. Most leading dividend distributors have moved past their high-growth days and have transitioned into stable, mature

Best Bang For Your Buck? 2 Bargain Stocks with 30%+ Upside: https://www.marketbeat.com/logos/articles/med_20250912104545_best-bang-for-your-buck-on-these-high-upside-barga.jpg
Best Bang For Your Buck? 2 Bargain Stocks with 30%+ Upside

When it comes to identifying target stocks for investment, compelling prospects may include companies that are undervalued and, simultaneously, expected to appreciate in the future.

Of course

DexCom Stock Just Fell to a 5-Year Low. Is It a No-Brainer Buy at This Price?: https://g.foolcdn.com/editorial/images/841661/someone-using-their-phone-to-check-their-glucose-levels.jpg
DexCom Stock Just Fell to a 5-Year Low. Is It a No-Brainer Buy at This Price?

It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you

1 Spectacular Growth Stock Down 20% to Buy Right Now, According to Wall Street: https://g.foolcdn.com/editorial/images/840891/person-using-a-cgm-system.jpg
1 Spectacular Growth Stock Down 20% to Buy Right Now, According to Wall Street

Since last year, DexCom (NASDAQ: DXCM) has faced a series of issues that have sunk its stock price. The medical device specialist's shares are down 20% over the trailing-12-month period and are

Why DexCom Stock Is Crashing Today: https://g.foolcdn.com/editorial/images/840622/gettyimages-2150701511.jpg
Why DexCom Stock Is Crashing Today

Shares of diabetes management equipment provider DexCom (NASDAQ: DXCM) had tumbled 17% by 11:15 a.m. ET on Friday, according to data provided by S&P Global Market Intelligence. The culprit was the

Should You Buy DexCom Stock Before Oct. 31?: https://g.foolcdn.com/editorial/images/839902/person-sitting-and-working-at-a-desk.jpg
Should You Buy DexCom Stock Before Oct. 31?

Shares of DexCom (NASDAQ: DXCM), a medical device specialist, have lagged the broader market so far in 2025, down 11% year to date. The diabetes-focused healthcare company has faced several legal

2 Stocks Down 17% and 21% to Buy Right Now: https://g.foolcdn.com/editorial/images/836498/person-using-a-cgm-system.jpg
2 Stocks Down 17% and 21% to Buy Right Now

One way to earn above-average market returns -- which isn't always easy -- is to invest in companies that have lagged the market but are likely to recover over the long run. As the basic investing

1 Growth Stock Down 40% to Buy Hand Over Fist Right Now: https://g.foolcdn.com/editorial/images/832943/person-using-a-cgm-system.jpg
1 Growth Stock Down 40% to Buy Hand Over Fist Right Now

Medical device specialist DexCom (NASDAQ: DXCM) has encountered significant headwinds since last year. The company's financial results in 2024 weren't nearly as strong as the market had expected

If You'd Invested $1,000 in DexCom 10 Years Ago, Here's How Much You'd Have Today: https://g.foolcdn.com/editorial/images/827361/patient-self-administering-a-shot.jpg
If You'd Invested $1,000 in DexCom 10 Years Ago, Here's How Much You'd Have Today

Shares of DexCom (NASDAQ: DXCM), a medical device specialist, have lagged the market this year. However, the true test of a company isn't how it performs over a relatively short period, such as

2 Stocks to Buy on the Dip and Hold for 10 Years
2 Stocks to Buy on the Dip and Hold for 10 Years

Despite President Donald Trump's trade wars and concerns about a possible recession, equity markets have performed relatively well this year, with the S&P 500 (SNPINDEX: ^GSPC) up 10% since January

DexCom (DXCM) Q2 Revenue Jumps 15%
DexCom (DXCM) Q2 Revenue Jumps 15%

DexCom (NASDAQ:DXCM) reported its second-quarter 2025 results on July 30, 2025, delivering an upbeat performance highlighted by a revenue beat and continued expansion in the key type 2 diabetes

Why This Beaten-Down Medical Device Stock Could Be Your Best Investment for the Next 5 Years
Why This Beaten-Down Medical Device Stock Could Be Your Best Investment for the Next 5 Years

Medical device specialist DexCom (NASDAQ: DXCM) has encountered significant headwinds in the past year. The company's financial results haven't been quite up to the market's standards, and broader

Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews
Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews


DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company’s one-of-a-kind NIL (Name, Image and Likeness) program

2 Stocks to Buy on the Dip and Hold for 10 Years
2 Stocks to Buy on the Dip and Hold for 10 Years

One of Warren Buffett's famous pieces of investing advice is to be greedy when others are fearful. One way to apply this wisdom is to look for companies that have lagged the market recently but

Dexcom Unveils New Report on Type 2 Diabetes Management in the U.S. at ADA 2025
Dexcom Unveils New Report on Type 2 Diabetes Management in the U.S. at ADA 2025


DexCom, Inc., the global leader in glucose biosensing, today released its "Dexcom State of Type 2 Report: Access and Attitudes Across the United States" ahead of the 85th Scientific Sessions of the

Prediction: These 2 Stocks Will Beat the Market in the Next Decade
Prediction: These 2 Stocks Will Beat the Market in the Next Decade

Investors typically want to beat the market over the long run. Though it's not an easy task, it certainly is possible with the right companies. Let's consider two corporations that could help you do

Dexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
Dexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance


DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2025.



Third Quarter 2025 Financial Highlights:




  • Revenue grew 22% year-over-year

Dexcom Appoints Euan Ashley to Board of Directors
Dexcom Appoints Euan Ashley to Board of Directors


DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025.



Dr. Ashley is a

Dexcom Schedules Third Quarter 2025 Earnings Release and Conference Call for October 30, 2025 at 4:30 p.m. Eastern Time.
Dexcom Schedules Third Quarter 2025 Earnings Release and Conference Call for October 30, 2025 at 4:30 p.m. Eastern Time.


DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2025 financial results after market close on Thursday, October 30, 2025. Management will hold a conference call

Dexcom Announces Upcoming Conference Presentations
Dexcom Announces Upcoming Conference Presentations


DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences:




  • The 2025 Wells Fargo Healthcare Conference on

Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan
Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan


DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2025.



Second Quarter 2025 Financial Highlights:




  • Revenue grew 15% year-over-year to

Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time.
Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time.


DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, July 30, 2025. Management will hold a conference call